fabiocrognale, Autore presso Nouscom

Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy

Research paper published in Science Translational Medicine by Nouscom and the Armenise-Harvard Laboratory of Immunoregulation at IIGM led by Luigia Pace describes how Nouscom’s adenoviral based [...]

Nouscom Announces Positive Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

NOUS-209 in combination with pembrolizumab is safe, highly immunogenic, and associated with promising early and long-term clinical efficacy in 20 MSI-H GI patients BASEL, Switzerland – 6th June [...]

Nouscom to Present Full Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

BASEL, Switzerland – 27th May 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced that full [...]

Nouscom Announces Promotion of Richard Davis to Chief Operating Officer

BASEL, Switzerland –23rd May 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the promotion [...]

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform

VAC85135 is a novel clinical candidate developed by Nouscom and Janssen under a multi-project agreement BASEL, Switzerland – 17th May 2022 – Nouscom, a clinical stage immuno-oncology [...]

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022

BASEL, Switzerland – 11th April 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced [...]

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Nouscom recently published in the Journal for ImmunoTherapy of Cancer a manuscript entitled: “Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, [...]

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an ‘off-the-shelf’ neoantigen cancer vaccine for the treatment of MSI-H solid tumors

Results presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting BASEL, Switzerland – 10th November 2021 – Nouscom, a clinical stage immuno-oncology company developing [...]

Nouscom AG: Abstract on interim results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at SITC

Our abstract “Phase 1 Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite [...]

Dr. Elisa Scarselli will join as Expert Speaker at the virtual Neoantigen Based Therapies Summit

Our Co-Founder and CSO Dr. Elisa Scarselli will join as Expert Speaker at the virtual Neoantigen Based Therapies Summit from October 26 – 28, 2021. Find out more about the conference and [...]